Stock Analysis
Elevance Health, Inc.ELV
P/E 18.71×· 4Y range 11.49–22.83×· 63th percentile of history
Sector: Healthcare · Industry: Healthcare Plans
AnalystsBuy29 analystsP/E 18.7× sits at the 63rd percentile of its 4.301163586584531-year history.
Cash covers 114% of debt · FY 2025.
PMP Verdict
Mixed fundamentals, fairly valued
Strengths
- Financial Health93
- Quality85
Risks
- Profitability35
- Growth43
Mixed picture — no clear quality or value edge.
Market context
-0.0% today· Z 0.5σ· ELV dropped 7.34% amid Q3 earnings concerns regarding a 4.9% premium decline and membership losses.
Bull Case
- ✓Altman Z 3.2 — safe-zone balance sheet
- ✓Interest coverage 11.1× — debt well covered
What's happening with ELV
Profile
Strong financial health, moat and earnings quality; profitability and growth lag behind.
How is each axis scored?
- Valuation70/100 · Moderate
- P/E vs own history (63th pct)5/25
- FCF yield (6.8%)20/25
- P/S (0.5x)25/25
- EV/EBIT (13.4x)20/25
- Growth43/100 · Weak
- Revenue CAGR (9.5%)12/25
- Net income CAGR (-1.9%)0/25
- EPS CAGR 5Y (0.3%)6/25
- Fwd implied growth (33.6%)25/25
- Profitability35/100 · Weak
- ROIC (13.2%)12/25
- ROE (11.3%)12/25
- Net margin (2.5%)6/25
- Operating margin (3.3%)5/25
- Financial Health93/100 · Strong
- Altman Z (3.20)25/25
- Current ratio (1.54)18/25
- Interest coverage (11.1x)25/25
- Net cash / debt (Net cash)25/25
- Quality85/100 · Strong
- Piotroski F (6/9)15/25
- Beneish M (-2.38)20/25
- FCF conversion (127%)25/25
- Margin stability (σ 1.2%)25/25
- Moat87/100 · Strong
- ROIC >12% years (10/10 yrs)25/25
- Median gross margin (91.7%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 2.8%)12/25
About Elevance Health, Inc.
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. Show more
The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states in government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
Headquarters: INDIANAPOLIS, IN · Employees: 97,100 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
70B+P/E (TTM)18.6xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 4Y history: 11.5x–22.8x · 63rd pct
P/FCF14.3xA
Grade A: CheapPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield6.8%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 4Y history: 0.6%–10.6% · 45th pct
P/S (TTM)0.46xA
Grade A: CheapPrice / TTM Revenue (own statements) — vs own 4Y history: 0.3x–0.9x · 30th pct
EV/EBIT13.4xB
Grade B: FairEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 4Y history: 8.2x–17.3x · 64th pct
EV/Sales0.6xA
Grade A: CheapEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E14.0xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio2.11xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio4.23D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield1.62%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio30.4%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
35DROIC13.2%C
Grade C: AverageNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE11.3%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA4.0%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin2.5%D
Grade D: LowNet Income / Revenue
Operating Margin3.3%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin89.1%A
Grade A: PremiumGross Profit / Revenue
FCF Margin3.1%D
Grade D: LowFCF / Revenue
True FCF Margin3.0%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
43D+Revenue CAGR9.5%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-1.9%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)0.3%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth33.6%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-12.5%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income4.9%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue0.1%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
93A+Altman Z-Score3.20A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.54xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.23xD
Grade D: Low(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage11.1xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.71xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt1.14xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
85APiotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.38A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion126.7%A
Grade A: StrongFCF / Net Income
Margin Stability1.2%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue0.6%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover1.62xA
Grade A: HighRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Kaye Mark Filed | Kaye Mark | Grant / award | +2.6K | |
Kaye Mark Filed | Kaye Mark | Tax withholding | -4161 | |
Wessling Erin M Filed | Wessling Erin M | Tax withholding | -255 | |
Wessling Erin M Filed | Wessling Erin M | Tax withholding | -94 | |
Craig Ryan R Filed | Craig Ryan R | Tax withholding | -144 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
BOUDREAUX GAIL Filed | BOUDREAUX GAIL | BuyOpen market buy | +2.0K | |
BOUDREAUX GAIL Filed | BOUDREAUX GAIL | BuyOpen market buy | +680 | |
PERU RAMIRO G Filed | PERU RAMIRO G | BuyOpen market buy | +1.0K |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
87AROIC >12% Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)91.7%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor2.8%C
Grade C: ModerateWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$22.88
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$46.48
Cash & short-term investments per share (Finnhub)
Book Value / Share$206.99
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$30.95B
Total debt obligations (short + long term)
Cash & Equiv.$35.38B
Cash and short-term investments
Net Debt$-4.43BA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$43.88B
Shareholders' equity (book value)
Asset / Liability1.57xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$92.48B
Current Market Capitalization
Beta0.64B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 16, 2026
Key Insights: Elevance Health, Inc. (ELV)
Piotroski F-Score of 6/9 indicates mixed fundamentals for Elevance Health, Inc.. Altman Z-Score of 3.20 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.38 suggests a low likelihood of earnings manipulation.
- Company is effectively debt-free after netting cash.
- At a valuation score of 70/100, ELV trades near the cheapest end of its own historical range (P/E 18.6).
See how ELV ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all ELV moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 9 | Regular | 414.27 | +3.32% | 3.09 |
| Oct 9 | After-hours | 411.70 | +2.68% | 2.54 |
Frequently Asked Questions about ELV
What is the current Elevance Health, Inc. (ELV) stock price?
ELV is trading at $428.26 at the last market close, down 0.04% on the session. PreMarketPrice tracks ELV pre-market, intraday and after-hours prices.
Is ELV stock a buy right now?
PreMarketPrice's quantitative model rates Elevance Health, Inc.'s financial health at 93/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is ELV stock overvalued?
Elevance Health, Inc. trades at a trailing P/E of 18.6 and our valuation score rates it 70/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Elevance Health, Inc. report earnings?
No confirmed earnings date is currently scheduled for ELV. The Earnings section lists recent reports and updates as dates are announced.
What sector does Elevance Health, Inc. operate in?
Elevance Health, Inc. operates in the Healthcare sector, within the Healthcare Plans industry. The Related Stocks section lists sector peers for comparison.
What does Elevance Health, Inc. do?
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025.
About Elevance Health, Inc. (ELV) Stock
Elevance Health, Inc. (ELV) is a US-listed stock operating in the Healthcare sector, specifically the Healthcare Plans industry. As of the latest update, Elevance Health, Inc. is trading at $428.26, down 0.04% on the day with a market capitalization of $92.5 billion. The financial health score for ELV is 93/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for ELV stock.
ELV Stock Analysis & Key Metrics
On PreMarketPrice, you can track Elevance Health, Inc. (ELV) across multiple dimensions:
- Pre-market price & movement: Real-time ELV stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for ELV with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Elevance Health, Inc. across multiple reporting periods.
- Financial health score: A composite score of 93/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for ELV.
- Sector peers: Compare ELV against 6 other healthcare stocks on key financial metrics.
Is ELV a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Elevance Health, Inc. (ELV) as an investment. The financial health score of 93/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Elevance Health, Inc. (ELV) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.